

Development of Statistical Computational Tools Through Pharmaceutical Drug Development and Manufacturing Life Cycle

Fasheng Li and Ke Wang

Abstract Statisticians at Pfizer who support Chemistry, Manufacturing, and Controls (CMC), and Regulatory Affairs (Reg CMC) have developed many statistical Rbased computational tools to enable high efficiency, consistency, and fast turnaround in their routine statistical support to drug product and manufacturing process development. Most tools have evolved into web-based applications for convenient access by statisticians and colleagues across the company. These tools cover a wide range of areas, such as product stability and shelf life or clinical use period estimation, process parameter criticality assessment, and design space exploration through experimental design and parametric bootstrapping. In this article, the general components of these R-programmed web-based computational tools are introduced, and their successful applications are demonstrated through an application of estimating a drug product shelf life based on stability data.

Keywords Statistical computing \cdot Web based tool \cdot R programming \cdot Regression analysis \cdot Design of experiment

1 Introduction

Through the regulatory, chemistry, manufacturing and controls (Reg CMC) development lifecycle of a drug product, a series of compendial requirements, quality standards, and performance criteria must be well established and met. It usually takes years to perform data collection, analysis, and reporting on chemical process, formulation and manufacturing process, and analytical method development. Common practice in current pharmaceutical industry to "optimize" product compositions,

© Pfizer, Inc. 2019 R. Liu and Y. Tsong (eds.), *Pharmaceutical Statistics*, Springer Proceedings in Mathematics & Statistics 218, https://doi.org/10.1007/978-3-319-67386-8_8

F. Li (🖂) · K. Wang

Pharmaceutical Science and Manufacturing Statistics, Pfizer Inc., MS 8220-2356, Eastern Point Road, Groton, CT 06340, USA e-mail: fasheng.li@pfizer.com

K. Wang e-mail: ke.wang2@pfizer.com

manufacturing processes, and analytical methods is to apply designed experiments (DOEs), statistical models and statistical sampling techniques. Data generated in these procedures, which could be in a large amount, are usually analyzed or evaluated by statisticians or statistically trained professionals with commercial statistical software systems such as Design Expert, SAS, or SAS-JMP. With the increasing demand of statistical application and the challenge of limited number of trained statisticians, it is desirable to develop computational tools to conduct routine statistical analyses in more efficient and consistent ways. The computational tools promote consistency, efficiency, and reproducibility for routine statistical analysis. Version control, monitoring and regular maintenance are an integral part of developing the computational tools. The features of the computational tools align well with the requirements of Title 21 Code of Federal Regulations (CFR) Part 11 that the software systems should be readily available for and subject to FDA inspection (3) [1]. Working as statisticians at Pfizer supporting pharmaceutical development and Reg CMC, we have identified many opportunities and areas that benefit from statistical computation tools. Most tools are developed using a language such as R and have evolved into web-based applications for easy access by statisticians and colleagues at Pfizer. This article introduces the general requirements and structure of web-based statistical tools. The computational application is demonstrated through one tool which evaluates product stability and predicts shelf life or clinical use period.

2 Overview of Available Web-Based Statistical Tools

2.1 Introduction of Components of Web-Based Statistical Applications

Figure 1 illustrates three standard components of typical web-based applications: computer server, GUI platform server and application user. In practice, applet authors utilize the application servers to construct the computation script and the graphical user interface (GUI) of the application, and ensure successful communication between the application servers (usually a web browser) and the computer servers. General users only need to compile data into a required format by the applications. For a statistical computational application, additional software systems, such as R and SAS need to be installed onto the computer server for statistical analysis. The following section provides an overview of the web-based statistical applications developed by Pfizer pharmaceutical development and Reg CMC statisticians.



Fig. 1 Components of a typical web-based application

2.2 Overview of Web-Based CMC Development/Regulatory Statistics Applications

Most computational tools developed at Pfizer to support analytical method, product, and process development are written in script codes using R, SAS, MATLAB, JMP, Minitab, or MS Excel spread sheet templates. One example is drug product shelf life prediction. Long-term stability data are collected under various storage conditions, per ICH Q1A (2) and are evaluated per ICH Q1E (1) [2, 3]. The statistical analysis is coded in SAS and R to generate summary results and plots.

The commercial software packages, nevertheless are important tools for statisticians to carry out data analysis. However, individual usage of the software presents issues in portability, limited version control, and reproducibility. With support from Pfizer Information Technology group, statisticians have been able to turn the individual pieces of code into web-based applications. Figure 2 illustrates various web-based statistical applications developed by the CMC statisticians at Pfizer and the targeted areas throughout the life cycle of drug development and manufacturing. These applications are searchable and accessible to Global Pfizer colleagues.



Fig. 2 Examples of statistical computational web-based applications throughout drug development and manufacturing life cycle

3 An Example Web-Based Statistical Computation Tool

Below, details are provided on the development and usage of one of the web-based applications listed in Fig. 2, Stability & Shelf Life Prediction.

For this application, assume that the stability data are collected from a registration stability program that follows ICH Q1A guidelines or a clinical stability program. Most stability programs have three registration batches per combination of strength, packaging configuration, and storage condition, whereas clinical stability program usually has only one batch. The online application of analyzing stability data is programmed in R, following ICH Q1E guidance for a specific combination of product, strength, package, and storage condition. The shelf life is determined by the decision criteria in the guidance. The clinical stability data is analyzed using a simple linear regression model, and the use period is determined, according to an internal criterion. For example, the use period of a clinical material is the shorter of the intersection of the 95% confidence interval and the specification limit or real stability time plus 12 months or longer if statistically supported. Therefore, the shelf life or clinical use period can be determined by a two-step procedure: model selection and projection of shelf life/use period.

3.1 Statistical Model Selection

For the statistical analysis of typical registration stability data, the following model selection procedure is performed based on the poolability of the data from the three batches. Assume $Y_b = y_{b1}, y_{b2}, \ldots, y_{bT}$ are the stability data for an attribute at time period $t = 1, 2, \ldots, T$ months for batch $b = 1, 2, \ldots, B$ for a certain combination of strength, package type, and storage condition.

(a) Fit a full model (the SSSI model—separate slopes and separate intercepts model):

$$y = \beta_0 + \beta_1 * time + \beta_{21} * batch + \beta_{12} * time * batch + \varepsilon$$
(1)

where the error \mathcal{E} is normally distributed with mean 0, and standard deviation σ . This model is referred to as the separate slopes and separate intercept model (SSSI), as it allows for different slopes and different intercepts for each batch.

Decision: If the p-value of the interaction of time and batch (time*batch) is <0.25, STOP and use Eq. (1) for the shelf life projection; if the p-value of the interaction of time and batch (time*batch) is \geq 0.25, GOTO step (b).

(b) Fit a reduced model (the CSSI model—common slope and separate intercepts model):

$$y = \beta_0 + \beta_1 * time + \beta_{21} * batch + \varepsilon$$
⁽²⁾

This model is referred to as a common slope and separate intercepts model (CSSI), as it permits the same slope estimate but different intercepts for all batches.

Decision: If the p-value of batch is <0.25, STOP and use Eq. (2) for the shelf life projection; if the p-value of batch is \geq 0.25, GOTO step (c).

(c) Fit a reduced model (the CSCI model—common slope and common intercept model):

$$y = \beta_0 + \beta_1 * time + \varepsilon \tag{3}$$

This model is referred to as a common slope and common intercept model (CSCI), since the same slope and intercept are used for all batches.

Decision: Eq. (3) is used for the shelf life projection.

The above described procedure for the statistical analysis of long-term registration stability data is summarized into a flow chart in Fig. 3. For typical one-batch clinical stability data, a simple linear regression model is used.



Fig. 3 Typical regression model selection per ICH Q1E stability data analysis

3.2 Shelf Life or Use-Period Projection

Once the regression model is determined, the 95% confidence interval (CI) can be calculated for any stability time point. The predicted shelf life/use period is determined as the shortest time point when the confidence limit intersects with the specification limit of the product. Notice that it is necessary to extrapolate the predictions and 95% CIs in order to determine the shelf life/use period beyond the maximum storage time of the stability data. Per ICH Q1E, the maximum extrapolation is two times of the maximum storage time (T_{max}) when T_{max} is <12 months or an extrapolation of 12 months when T_{max} is > = 12 months. Figure 4 illustrates how to establish the shelf life for an example data set. For this set of stability data, a separate slope and separate intercept model is selected and the shelf life is determined by the limiting lot (i.e. Lot 3). This shelf life limiting lot is determined, due to its fastest impurity A growth (largest slope) and thus its 95% CI intercepts with the specification limit of 1%, the earliest at 32.1 months. Therefore, 32.1 months (or 32 months) is the longest shelf life can be proposed. Practically, a shelf life of either 24 months or 30 months can be proposed for this product based on this set of data.



Fig. 4 Prediction of product shelf life based on regression model per ICH Q1E stability analysis: the predicted shelf life is the interception point (i.e., 32.1 months) of the upper 95% confidence limit with specification limit (i.e. the upper limit 1.0%)

3.3 The Internal Web-Based Online Application

Both long-term registration stability data and clinical stability data are collected routinely for all filed products. The repeated stability data analysis, including stability data plotting and drug product shelf life prediction, necessitated the development of a web-based application tool to standardize these statistical activities.

The web application for Registration and Clinical Stability Data Analysis and Shelflife/Use Period Prediction is programmed in R. A graphical user interface (GUI) is built to allow users to upload the relevant stability data to the program for analysis. The GUI of this application is displayed in Figs. 5 and 6 where the main interface contains links to various features, such as the user manual, example data sets in required formats, dialogues for uploading data, and choices of analyses.

Once stability data is uploaded and choices of statistical analyses and parameters are determined, the job is submitted and run in the background through the HPC computing cluster. As soon as the job is finished, users can view the results (including tables and graphical plots) through the web browser (e.g., Internet Explorer, Chrome). The application also provides the ability to download tables and graphs as well as consolidating the results in a .pdf formatted report. Figure 6a, b are snapshots of the output on a web browser.

(a) Welcome to the Online Tool of
Shelf Life/Use Period Prediction Based on Registration or Clinical Stability Data
PharmSci-PGS Statistics PTx Pharmaceutical Sciences Pfizer Worldwide Research and Development Eastern Point Road Groton, CT 06340
Got a question? Please Contact:
User Guide and Example Datasets
User Guide: Open Example Data File For Multiple Batches Open For Single Batch Open For LIMS Exported Data Open
Upload Data:1. Browse for .csv files (click above for examples); 2. Upload file to EASA
Data File Choose File No file chosen Upload Note: data files must be text files with COMMA (.) as DELIMITER Standard Data Format or Directly Exported from LIMS Standard Data Format LIMS Export
Submit (scroll down to the end of page) after the following selections:
Type of Analysis • Shelf Life for Registration Use Period for Clinical Yes Type of Only Stability Specification Setting
Submit

Fig. 5 a Web-based application—registration and clinical stability data analysis and shelflife/use period prediction: GUI—main interface b Web-based application—registration and clinical stability data analysis and shelflife/use period prediction: GUI—further dialogues

Development of Statistical Computational Tools through Pharmaceutical ...

ters help kenne Analyses			
ol by a Variable?	NA T	Adjustment coefficients for y-axis:	0.9, 1.1
infidence Level:	0.95	Color of the Regression Line:	Black Y
pe of Confidence Limit to Use:	Confidence ¥	Use Color for Plot Symbols	Black V
value to Determine Poolability:	0.25	Symbol Size for Plot:	1.5
nimum number of time points for a batch	3	Size for Axis Label:	1.5
RT Transformation of Stability Time?	None T	Tick Size for Axis:	1.3
it of Stability Time: Month, Week, Day, Date	Month ¥	Points Connected?	No 🔻
M/DD/YYYY) w many text lines per page for summary report	2 20	Draw Specification on Plot?	Yes T
		Plot similar to for filing?	No ¥
aneous Analyses and Plots erate z-scores? merate Z-Scores for Attributes?	No ¥		
ancous Analyses and Piots erate z-scores? merate Z-Scores for Attributes? ust Initali Values at Time 0, Change Default 8;	No V	hellife?	
aneous Analyses and Piots arate z-scores? nerate Z-Scores for Attributes? st Initiall Values at Time 0, Change Default S just initial values at time 0, change specs, d/or expected shelflife?	No Change Expected S No	helflife?	
ancous Analyses and Plots erate z-scores? Inerate Z-Scores for Attributes? Ist Initali Values at Time 0, Change Default S just Initial values at time 0, change specs, dior expected shellfifa? diagnostic plots and perform risk assessme	No V Pec, or Change Expected S No V	hellife? CQAs	
aneous Analyses and Piots erate z-scores? inerate Z-Scores for Attributes? ist initial Values at Time 0, Change Default S just initial values at time 0, change specs, doir expected shellfife? diagnostic plots and perform risk assessme eate diagnostic plots for linear regression dois (not for Data Piot Only)?	No V pec, or Change Expected S No V nt for non-shiftlife limiting s	helflife? CQAs	
aneous Analyses and Plots prate z-scores? nerate Z-Scores for Altributes? st Initial Values at Time 0. Change Default S just initial values at time 0, change specs, dior expected shellfile? diagnostic plots and perform risk assessme pate diagnostic plots for linear regression dels (not for Data Plot Only)? form risk assessment for non-shellfile limiting JAS?	No V No V No V No V No V	heffilfe? CQAs	
aneous Analyses and Plots srate z-scores? nerate z-scores for Attributes? st initial Values at Time 0, Change Default S iust initial values at time 0, change specs, dior expected shellfile? diagnostic plots and perform risk assessme sate diagnostic plots for linear regression deis (not for Data Plot Only)? rform risk assessment for non-shellfile limiting JA-? strate Summary of Stability Data and Siopes	No V Pec, or Change Expected S No V Int for non-shiftlife limiting to No V No V for Stability Batches	heffilfe? COAs	
Ianeous Analyses and Piots erate z-scores? enerate Z-Scores for Attributes? Just Initial Values at Time 0, Change Default S just Initial Values at Time 0, change Default S just Initial Values at time 0, change specs, diagnostic plots and perform risk assessme reate diagnostic plots for linear regression dels (not for Data Piot Only)? prform risk assessment for non-shelflife limiting DAS? erate Summary of Stability Data and Slopes enerate a summary table of stability data formation	No V pec, or Change Expected S No V nt for non-shiftlife limiting No V No V For Stability Batches No V	helfilfe? CQAs	

Fig. 5 (continued)

In summary, the implementation of the web-based statistical application of "registration and clinical stability data analysis and shelflife/use period prediction" is able to offer benefits and features such as,

- Align the statistical analyses of long term stability data
- Offer quick and convenient turnaround to analyze stability data, to generate shelf life plots and tables, and summary report
- Allow easy maintenance for feature updates due to the version controlled R program
- Run jobs in the background on HPC cluster or cloud computers.

4 Conclusions

The benefits and features of web-based statistical applications have been demonstrated through a selected program "registration and clinical stability data analysis and shelflife/use period prediction". Statisticians and scientists supporting drug development and Reg CMC areas can offer their routine statistical activities with

(a)

1 . Data Read-In Data Analyzed.csv (click to Open or Save)

ſ	PRODUCT	STRENGTH	STORAGE CONDITION	PACKAGE	LOT	METHOD	TIME	RESULT	SPECIFICATION	EXPIRY
6	Product B	x mg	25C/60%RH	bottle	Lot 1	assay	0	100	95-105	24
6	Product B	x mg	25C/60%RH	bottle	Lot 1	assay	3	98	95-105	24
6	Product B	x mg	25C/60%RH	bottle	Lot 1	assay	6	98	95-105	24
14	Product B	x mg	25C/60%RH	bottle	Lot 1	assay	9	100	95-105	24
5	Product B	x mg	25C/60%RH	bottle	Lot 1	assay	12	99	95-105	24
6	Product B	x mg	30C/65%RH	bottle	Lot 1	assay	0	100	95-105	24
IC:				E						1000

2 . Summary of Shelflife Prediction

ShelfLife Estimate.csv (click to Open or Save)

ſ	Product	Strength	strength Storage condition		Response	Model	Lot	Pred Shelf Life	Q1E Shelf Life
1	Product B	x mg	25C/60%RH	bottle	assay	Maximum Allowable	Expiry	10	10
2	Product B	x mg	25C/60%RH	bottle	assay	SSSI	Lot 1	18	18
3	Product B	x mg	25C/60%RH	bottle	assay	SSSI	Lot 2	16	16
4	Product B	x mg	25C/60%RH	bottle	assay	SSSI	Lot 3	10	10

3. Plots of Shelf Life Prediction

ShelfeLifePlots.pdf (click to Open or Save)



4 . Summary of Stability Data Info

Stability_Data_Information_Summary.csv (click to Open or Save)

Г	PRODUCT	STRENGTH	STORAGE CONDITION	PACKAGE	Lot	Time Point	Attribute	Specification
[Product B	x mg	25C/60%RH	bottle	Lot 1, Lot 2, Lot 3	0, 3, 6, 9, 12	assay	assay: 95-105
2	Product B	y mg	25C/60%RH	bottle	Lot 4, Lot 5, Lot 6	0, 3, 6, 9, 12	~	assay: 95-105
3	Product B	x mg	30C/65%RH	bottle	Lot 1, Lot 2, Lot 3	0, 3, 6, 9, 12	~	assay: 95-105
6	Product B	y mg	30C/65%RH	bottle	Lot 4, Lot 5, Lot 6	0, 3, 6, 9, 12	~	assay: 95-105

5 . Slopes of CQAs

Stability_Data_Slope_Summary.csv (click to Open or Save)

Г	PRODUCT	STRENGTH	STORAGE CONDITION	PACKAGE	Response	Model	Lot	Pred Shelf Life	Intercept	Slope	P-Value
Ī	Product B	x mg	25C/60%RH	bottle	assay	SSSI	Lot I	18	99	-0.033	0.852
	Product B	x mg	25C/60%RH	bottle	assay	SSSI	Lot 2	16	99	-0.055	0.758
3	Product B	x mg	25C/60%RH	bottle	assay	SSS1	Lot 3	10	101	-0.447	0.030
4	Product B	x mg	30C/65%RH	bottle	assay	CSC1	Lot I	15	100	-0.195	0.040

6 . Summary Statistics of CQA Slopes

Stability_Data_Slope_Summary_Statistics.csv (click to Open or Save)

PRODUC	T STRENGTH	STORAGE CONDITION	PACKAGE	Response	N Batches	-	Mean Slope	Min Slope	Max Slope	sqrt(Total Variance)	sqrt(Between Batch Variance)	sqrt(Within Batch Variance)	Mean+3*StDe
1 Product B	x mg	25C/60%RH	bottle	assay	3	3	-0.18	-0.45	-0.033	0.23	0.22	0.082	0.52
2 Product B	y mg	25C/60%RH	bottle	assay	3	3	-0.15	-0.15	-0.150	0.00	0.00	0.000	-0.15
3 Product B	x mg	30C/65%RH	bottle	assay	3	3	-0.19	-0.19	-0.195	0.00	0.00	0.000	-0.19
4 Product B	y mg	30C/65%RH	bottle	assay	3	3	-0.10	-0.10	-0.105	0.00	0.00	0.000	-0.10

7 . Report of Stability Data Analysis

Stability Data Analysis Report.pdf (click to Open or Save)

Run by: Fasheng Li Date run: 28-Aug-2017 15:16

Fig. 6 a Abbreviated Result—displayed in a browser of the web-based application—registration and clinical stability data analysis and shelflife/use period prediction: Data read-in, shelf life results and plots **b** Abbreviated Result—displayed in a browser of the web-based application—registration and clinical stability data analysis and shelflife/use period prediction: Summary of data, slopes, reports, etc.

increased consistency, improved efficiency, better alignment of statistical analyses, and easily retrievable results by deploying web-based statistical applications. These web-based statistical applications can standardize statistical approaches, centralize software pieces, validate and verify software pieces, and utilize high performance and cloud computer resources.

Acknowledgements The authors acknowledge Kimberly Vukovinsky, Robert J. Timpano, and colleagues in Pharmaceutical Science and Manufacturing Statistics group at Pfizer for their generous support of evaluating and commenting the web-based applications.

References

- 1. US Food and Drug Administration Department of Health and Human Services. 21 CFR 11: Electronic records; electronic signatures (2017)
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Q1E: Evaluation for Stability Data (2004)
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Q1A (R2): Stability Testing of New Drug Substances and Products (2003)